Results: 4

1.
Figure 4

Figure 4. Pulmonary Function in Patients with Lymphangioleiomyomatosis. From: Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis.

Panel A shows the forced expiratory volume in 1 second (FEV1) for each patient. Panel B shows the forced vital capacity (FVC) for each patient. Panel C shows the mean change (in milliliters) from the baseline values for FEV1 and for FVC. I bars indicate the standard errors. Panel D shows the residual volume for each patient.

John J. Bissler, et al. N Engl J Med. ;358(2):140-151.
2.
Figure 3

Figure 3. Renal Angiomyolipomas in the Abdomen of a Patient with the Tuberous Sclerosis Complex. From: Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis.

Bilateral angiomyolipomas are shown at baseline and after 12 months of sirolimus therapy. Three lesions in the left kidney are identified by arrows; at 12 months, the top lesion had become reduced in size and the bottom two had become imperceptible. The images were obtained with the use of fast spin–echo T2-weighted magnetic resonance imaging with fat suppression.

John J. Bissler, et al. N Engl J Med. ;358(2):140-151.
3.
Figure 1

Figure 1. Overview of Screening, Enrollment, and Follow-up of the Patients with the Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM). From: Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis.

Angiomyolipoma volumes and pulmonary-function tests in patients with LAM were assessed during the period of sirolimus treatment, from baseline to 12 months, and during a post-treatment observation period, from 12 to 24 months. At baseline, 18 patients had LAM, but pulmonary data were uninterpretable in 2 patients because of chylothorax or pneumothorax. At the 12-month time point, one patient declined to undergo pulmonary-function tests, and four patients had withdrawn from the study. One patient withdrew during the second year.

John J. Bissler, et al. N Engl J Med. ;358(2):140-151.
4.
Figure 2

Figure 2. Angiomyolipoma Volume in the Patients with the Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis during the Study. From: Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis.

Angiomyolipomas were visualized with the use of abdominal magnetic resonance imaging, and volumetric analysis was performed at baseline and at 2, 4, 6, 12, 18, and 24 months. The angiomyolipoma volume at each visit is expressed as a percentage of the baseline size. The dashed line represents 70% of the baseline value; data below the line indicate that the mean angiomyolipoma volume was reduced by 30% or more.

John J. Bissler, et al. N Engl J Med. ;358(2):140-151.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk